Iron chelators inhibit human platelet aggregation, thromboxane A2 synthesis and lipoxygenase activity

Abstract

The iron chelators desferrioxamine and 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one (L1) inhibited human platelet aggregation in vitro as well as thromboxane A₂ synthesis and conversion of arachidonate to lipoxygenase‐derived products. Non‐chelating compounds related to L1 were without effect on cyclooxygenase or lipoxygenase activity. Since both cyclooxygenase and lipoxygenase are iron‐containing enzymes, it is suggested that the inhibition of platelet function by these iron chelators may be related to the removal or binding of iron associated with these enzymes. These iron chelators may therefore be of potential therapeutic value as platelet antiaggregatory agents and of possible use in the treatment of atherosclerotic and inflammatory joint diseases.